Logo
x

Search

Subscribe Now

inflammatory bowel disease

Genentech Enters into a Multi-Year Research Collaboration with Novome Biotechnologies to Develop Targets Against Inflammatory Bowel Disease

Genentech Enters into a Multi-Year Research Collaboration with Novome Biotechnologies to Develop Targets Against Inflammatory Bowe...

  • November 11, 2021
AzurRx Signs a Reverse Triangular Merger Agreement to Acquire First Wave Bio for ~$229M

AzurRx Signs a Reverse Triangular Merger Agreement to Acquire First Wave Bio for ~$229M

  • September 14, 2021
Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease

Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for Inflammatory Bowel Disease

  • September 3, 2020
Celltrion's Remsima SC (biosimilar- infliximab) Receives CHMP's Positive Opinion for an Additional Five Indications Including Inflammatory Bowel Disease and Ankylosing Spondylitis

Celltrion's Remsima SC (biosimilar- infliximab) Receives CHMP's Positive Opinion for an Additional Five Indications Including Infl...

  • June 30, 2020
Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease

Synlogic Terminates its Agreement with AbbVie for Synthetic Biotic Medicines to Treat Inflammatory Bowel Disease

  • May 21, 2020
Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowe...

  • April 6, 2020
Celltrion Presents the Long-Term Data for CT-P13 (Biosimilar, Infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024

    Celltrion Presents the Long-Term Data for CT-P13 (Biosimilar, Infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024

    • February 23, 2024
    Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn

      Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn's Disease in...

      • December 19, 2023
      Disease of the Month - Ulcerative Colitis

        Disease of the Month - Ulcerative Colitis

        • November 28, 2023
        Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK

          Sosei Heptares Initiates to Reclaim Ownership GSK4381406 from GSK

          • November 24, 2023
          Easing the Storm: Tackling Ulcerative Colitis Flare-ups Effectively

            Easing the Storm: Tackling Ulcerative Colitis Flare-ups Effectively

            • November 10, 2023
            Roche Reports the Acquisition of Telavant along with its Asset RVT-3101 from Roivant for the Treatment of Inflammatory Bowel Disease

              Roche Reports the Acquisition of Telavant along with its Asset RVT-3101 from Roivant for the Treatment of Inflammatory Bowel Disea...

              • October 23, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.